alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 10.3**

**PLAINS EXPLORATION & PRODUCTION COMPANY**

**FIRST AMENDMENT TO**

**EMPLOYMENT AGREEMENT**

**WHEREAS**, effective as of November 8, 2006, PlainsExploration & Production Company (the “Company”) entered into an employment agreement (the “Agreement”) with Doss R. Bourgeois (the “Employee”); and 

**WHEREAS**, the Company and the Employee have agreed to amend the Agreement as set forth below; 

**NOW, THEREFORE**, the Company and the Employee agree that Paragraph 6(c)(vi) of the Agreement shall be amended by deleting the reference toSections 6(c)(iii) and (iv). 

**IN WITNESS WHEREOF**, the Company and the Employee have executed this First Amendment on the26th day of April, 2007. 

 

**PLAINS EXPLORATION & PRODUCTION COMPANY**

By:
 
/s/ James C. Flores
 
James C. Flores
 
Chief Executive Officer, President and Chairman of the Board

**EMPLOYEE**

/s/ Doss R. Bourgeois

Doss R. Bourgeois
Exhibit 4.376

 

/Emblem of the Russian Federation/

 

FEDERAL SERVICE FOR SUPERVISION IN THE SPHERE OF COMMUNICATIONS, INFORMATION TECHNOLOGY AND MASS MEDIA

 

LICENSE

 

No. 172079 dated August 01, 2018

 

For Rendering

 

telematic services

 

This License is granted to

 

Joint Stock Company

 

RIKT

 

Primary State Registration Number of a Legal Entity 
 (Individual Entrepreneur) (OGRN, OGRNIP)

 

1034214000215

 

Tax Identification Number (TIN)

 

4214004610

 











 

Location address (place of residence):

 

9, Chekhova str., Mezhdurechensk, Kemerovo region, 652870

 

The territory covered by telecommunications services is specified in the Appendix.

 

This License is granted for a term:

 

until August 01, 2023.

 

This License is granted by decision of the licensing body - Order dated February 26, 2019 No. 111-рчс

 

Appendix being an integral part of this license is executed on 2 sheets.

 

 

	
Deputy Head
    	
/signature/   A.A.Pankov
    
	
 
    	
 
    
	
Stamp here
    	
 
    
	
Official   seal:
    	
 
    
	
MINISTRY OF TELECOM AND   MASS COMMUNICATIONS
    	
 
    
	
OF THE RUSSIAN   FEDERATION
    	
 
    
	
FEDERAL SERVICE FOR   SUPERVISION IN THE SPHERE
    	
 
    
	
OF   COMMUNICATIONS, INFORMATION TECHNOLOGY
    	
 
    
	
AND MASS MEDIA
    	
 
    
	
PSRN 1087746736296
# Sitemap

## November 30, 2016

- Home
- Sitemap
- 2016
- 11
- November 30, 2016

            - Mary W. Jackson at NASA Langley
            - Mary Jackson at NASA Langley
            - Mary W, Jackson at NASA Langley
            - Sen. John Glenn and Neil Armstrong at 50th Anniversary Celebration of Friendship 7
            - Otto (was TD16 – Atlantic Ocean)
            - John Marmie Talks About NASA’s Plan To Mine A Near-Earth Asteroid
            - Liftoff of Alan Shepard’s Freedom 7 Mission
            - Syrtis Major – False Color
            - Staff of Supersonic Pressure Tunnel and Computers, 1950s
            - Dorothy Vaughan
<PAGE>   1


                                                                 EXHIBIT 10.149

                                   DEMAND NOTE

$350,000.00                                                   New York, New York
                                                                  August 9, 1999

        FOR VALUE RECEIVED, the undersigned, Wilshire Technologies, Inc. a
California corporation (hereinafter referred to as "Borrower"), hereby
unconditionally PROMISES TO PAY to the order to TRILON DOMINION PARTNERS, LLC, a
Delaware limited liability company ("Lender"), at 245 Park Avenue, 28th Floor,
New York, NY 10167, or at such other place as the holder of this Demand Note may
designate from time to time in writing, in lawful money of the United States of
America and in immediately available funds, the principal amount of Three
Hundred Fifty Thousand and 00/100, DOLLARS ($350,000.00), together with interest
on the unpaid principal amount of this Demand Note outstanding from time to time
from the date hereof, at a rate per annum equal to the Prime rate of interest
plus 3.0%, or the highest rate permitted by law, whichever shall be less.

        The principal amount of the indebtedness evidenced hereby shall be
payable on demand. Interest thereon shall be paid when principal is paid from
the date hereof until such principal amount is paid in full at such interest
rate as specified above. Following failure to pay on demand, Borrower agrees to
pay interest on any overdue payment of principal at a rate per annum equal to
the stated interest rate plus 5%, or the highest rate permitted by law,
whichever shall be less. All interest calculations shall be computed on the
basis of a 360 day year.

        Demand, presentment, protest and notice of nonpayment and protest are
hereby waived by Borrower.

        Borrower shall have no right to make any off-set against or deduct from
any payment due under this Demand Note.

        Principal and interest may be prepaid at any time without penalty.

        This Demand Note may not be changed orally, but only by an agreement in
writing and signed by the party against whom enforcement of such change is
sought.

        All covenants of Borrower in this Demand Note and all rights of the
holder under this Demand Note shall bind Borrower and its successors and
assigns, and all such covenants and rights shall inure to the benefit of the
holder of this Demand Note and its successors and assigns.



                                       1
<PAGE>   2

        This Demand Note has been delivered and accepted at New York, New York
and shall be interpreted, governed by, and construed in accordance with, the
laws of the State of New York.

                                               Wilshire Technologies, Inc.


                                                By : /s/ Kathleen E. Terry
                                                     -------------------------
                                                Name:  Kathleen E. Terry
                                                Title: Chief Financial Officer


                                       2
#### STATE OF NEW JERSEY v. THEODORE WATROUS.

April 28, 1987.

Petition for certification denied.
EXHIBIT 32.1

SECTION 906 CERTIFICATION - CEO

In connection with the Quarterly Report of Plains Exploration & Production Company
(the Company) on Form 10-Q for the period ending March 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James C. Flores, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

To the best of my knowledge,
after reasonable investigation:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------

Dated: May 7, 2009



/s/ James C. FloresJames C. Flores Chief Executive Officer


The foregoing certification is being furnished solely pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document.

A signed original of this written
statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been
provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
<TABLE>
                                        
                          The Multicare Companies, Inc.
                        Computation of earnings per share
                                        
                               September 30, 1996
                                        
                                   (Unaudited)
                                        
                      (in thousands, except per share data)
<CAPTION>

                                         Three months ended  Nine months ended
                                         September 30, 1996  September 30, 1996

<S>                                          <C>                <C>
Income per common and common
 equivalent share:
Income before extraordinary item             $ 7,418            20,395
Net Income                                   $ 7,418            18,914

Weighted average number of common
and common equivalent shares outstanding       27,606           27,506
Income before extraordinary item per common
  and common equivalent share                $ .27              .74
Net income per common and common
  equivalent share                           $ .27              .69

Income per common and common
equivalent share assuming full dilution:
Income before extraordinary item             $ 7,418            20,395

Net income                                   $ 7,418            18,914
Adjustments to income:
Interest expense and amortization of debt
  issuance costs relating to convertible
  debt, net of tax                           $ 982              2,973
Adjusted net income                          $ 8,400            21,887

Weighted average number of common and
  common equivalent shares outstanding         27,798           27,772
Convertible debt shares                        4,976            4,976
Adjusted shares                                32,774           32,748

Income before extraordinary item per
  common share assuming full dilution        $ .26              .71

Net income per common share assuming
full dilution                                $ .26              .67
</TABLE>
#### STATE OF NEW JERSEY v. JOHN HENRY ROSS.

May 19, 1987.

Petition for certification denied.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Small Business Administration [Disaster Declaration #12349 and #12350]
 AGENCY: U.S. Small Business Administration.
 ACTION: Notice.
 SUMMARY: This is a Notice of the Presidential declaration of a major disaster for Public Assistance only for the State of Minnesota (FEMA-1941-DR), dated 10/13/2010. *Incident:*
                         Severe storms and flooding. *Incident Period:*
                         09/22/2010 and continuing. *Effective Date:*
                         10/13/2010. *Physical Loan Application Deadline Date:*
                         12/13/2010. *Economic Injury (EIDL) Loan Application Deadline Date:*
                         07/13/2011.
 ADDRESSES: Submit completed loan applications to: U.S. Small Business Administration, Processing and Disbursement Center, 14925 Kingsport Road, Fort Worth, TX 76155.
 FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster Assistance, U.S. Small Business Administration, 409 3rd Street, SW., Suite 6050, Washington, DC 20416.


SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of the President's major disaster declaration on 10/13/2010, Private Non-Profit organizations that provide essential services of governmental nature may file disaster loan applications at the address listed above or other locally announced locations. The following areas have been determined to be adversely affected by the disaster: *Primary Counties:*
                     Blue Earth, Cottonwood, Dodge, Faribault, Freeborn, Goodhue, Jackson, Lincoln, Lyon, Martin, Mower, Murray, Olmsted, Pipestone, Rice, Rock, Steele, Wabasha, Waseca, Watonwan, Winona. The Interest Rates are: Percent*For Physical Damage:*Non-Profit Organizations With Credit Available Elsewhere
3.625Non-Profit Organizations Without Credit Available Elsewhere
3.000*For Economic Injury:*Non-Profit Organizations Without Credit Available Elsewhere
3.000
 The number assigned to this disaster for physical damage is 12349B and for economic injury is 12350B. (Catalog of Federal Domestic Assistance Numbers 59002 and 59008) James E. Rivera, Associate Administrator for Disaster Assistance.


[FR Doc. 2010-26786 Filed 10-21-10; 8:45 am] BILLING CODE 8025-01-P
kura-ex107_85.htm



 

Exhibit 10.7

2nd Amendment To Sublease

This 2nd Amendment To Sublease (this “Amendment”), dated as of April 22, 2020 (“Amendment Effective Date”), by and between Araxes Pharma LLC, a Delaware limited liability company (“Sublandlord”), and Kura Oncology, Inc., a Delaware corporation (“Subtenant”).

Whereas, Sublandlord (as successor-in-interest to Wellspring Biosciences, Inc., a Delaware corporation (“Prior Sublandlord”)) and ARE-SD Region No. 35, LLC, a Delaware limited liability company (“Landlord”) are parties to that certain Lease Agreement dated as of December 20, 2016 (as may be amended, supplemented or otherwise modified from time to time, the “Master Lease”), with respect to certain premises located at 3033 Science Park Road, San Diego, California as more particularly described in the Master Lease (the “Master Premises”);

Whereas, Sublandlord (as successor-in-interest to Prior Sublandlord pursuant to that certain Assignment and Assumption of Sublease dated August 2, 2019) and Subtenant are parties to that certain Sublease dated as of December 20, 2016, as amended by that certain 1st Amendment to Sublease dated March 1, 2019 (the “Sublease”), with respect to a portion of the Master Premises as more particularly described in the Sublease (the “Subleased Premises”); and

Whereas, the Term of the Sublease is scheduled to expire on April 30, 2020 (“Current Expiration Date”), Subtenant has expressed its inability to vacate the Subleased Premises on or prior to the Current Expiration Date, and the parties now desire to amend the Sublease as set forth herein.

Now, Therefore, in consideration of the various covenants and agreements hereinafter set forth, the parties hereto agree as follows:

1.Section 2 of the Sublease is hereby amended to extend the expiration date of the Term of the Sublease to June 30, 2020.

2.Except as amended as described above, all other terms and conditions of the Sublease will remain in full force and effect.

3.Initially capitalized terms used but not defined herein shall have the meanings given to them in the Sublease. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute a single instrument.

 

[Remainder of Page Left Intentionally Blank]


 



 

 

In Witness Whereof, the parties hereto have executed this Amendment effective as of the Amendment Effective Date.

 


			
	
SUBLANDLORD:
	
 
	
SUBTENANT:

	
 
	
 
	
 

	
ARAXES PHARMA LLC,
	
 
	
KURA ONCOLOGY, INC.,

	
a Delaware limited liability company
	
 
	
a Delaware corporation

	
 
	
 
	
 

	
 
	
 
	
 

	
By:  /s/ Troy E. Wilson
	
 
	
By:  /s/ Marc Grasso

	
Name:  Troy E. Wilson
	
 
	
Name:  Marc Grasso

	
Title:    Sole Managing Member
	
 
	
Title:    CFO & CBO




 

[Signature Page to 2nd Amendment to Sublease]
[Federal Register Volume 75, Number 202 (Wednesday, October 20, 2010)]
[Notices]
[Page 64745]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-26469]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 20, 2010, Halo 
Pharmaceutical Inc., 30 North Jefferson Road, Whippany, New Jersey 
07981, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
basic classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    Dihydromorphine is an intermediate in the manufacture of 
Hydromorphone and is not for commercial distribution. The company plans 
to manufacture Hydromorphone HCL for sale to other manufacturers and 
for the manufacture of other controlled substance dosage units for 
distribution to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than December 20, 2010.

    Dated: October 8, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-26469 Filed 10-19-10; 8:45 am]
BILLING CODE 4410-09-P
#### STATE OF NEW JERSEY v. ALTHERIA GREEN.

May 19, 1987.

Petition for certification denied.
<PAGE>   1

                                                                      EXHIBIT 11

                           SI DIAMOND TECHNOLOGY, INC.

                  COMPUTATION OF INCOME (LOSS) PER COMMON SHARE


<TABLE>
<CAPTION>

                                                                 Three Months ended March 31,
                                                               ---------------------------------
                                                                   2000                 1999
                                                               ------------          -----------

<S>                                                            <C>                   <C>
Computation of income (loss) per common share:

   Net income (loss) applicable to common stockholders         $ (1,382,186)         $ 3,332,039

   Weighted average number of common shares
         outstanding                                             54,236,200           47,798,022

   Net income (loss) per common share                          $      (0.03)         $      0.07



Computation of income (loss) per common share
   assuming full dilution:

   Net income (loss) applicable to common stockholders                                 3,332,039

   Plus: Income impact of assumed conversions
        Preferred stock dividends                                                         38,945
        Interest on convertible notes                                                     21,834

   Income available to common stockholders
        assuming conversion                                                            3,392,818

   Weighted average number of common
        Shares outstanding                                                            47,798,022


   Plus incremental shares from dilutive securities
        Convertible preferred stock                                                    1,959,297
        Convertible notes payable                                                      2,435,660
        Warrants                                                                         246,616
       Options                                                                         2,413,357

   Adjusted weighted average number of
        common shares                                                                 54,852,952

Net income (loss) per common share                                                          0.06
</TABLE>


No computation of diluted loss per common share is included for the 2000 period
 because such Computation results in an antidilutive loss per common share.
EXHIBIT 31.1Cronos Global Income Fund XIV, L.P.Rule 13a-14 CERTIFICATION     I, Dennis J. Tietz, certify that:     1. I have reviewed this quarterly report on Form 10-Q of Cronos Global Income Fund XIV, L.P.(the “Partnership”);     2. Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to the periodcovered by this quarterly report;     3. Based on my knowledge, the financial statements, and other financial information includedin this quarterly report, fairly present in all material respects the financial condition, resultsof operations and cash flows of the Partnership as of, and for, the periods presented in thisquarterly report;     4. The other certifying officer of Cronos Capital Corp. (“CCC”), the General Partner of thePartnership, and I are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Partnership and wehave:          (a) designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that material information relating tothe Partnership, including its consolidated subsidiaries, is made known to us by others withinthose entities, particularly during the period in which this quarterly report is being prepared;and          (b) evaluated the effectiveness of the Partnership’s disclosure controls and procedures andpresented in this quarterly report our conclusions about the effectiveness of the disclosurecontrols and procedures, based on our evaluation; and          (c) disclosed in this quarterly report any change in the Partnership’s internal control overfinancial reporting that occurred during the Partnership’s most recent fiscal quarter (thePartnership’s fourth fiscal quarter in the case of an annual report) that has materially affected,or is reasonably likely to materially affect, the Partnership’s internal control over financialreporting.     5. CCC’s other certifying officer and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the Partnership’s auditors and the Audit Committeeof Partnership’s Board of Directors (or persons performing the equivalent function):          (a) all significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affect thePartnership’s ability to record, process, summarize and report financial information; and          (b) any fraud, whether or not material, that involves management or other employees who havea significant role in the Partnership’s internal control over financial reporting.      Date: May 15, 2006   /s/ DENNIS J TIETZ     Dennis J Tietz  President of CCC  (Chief Executive Officer)